Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 5
2000 10
2001 27
2002 22
2003 30
2004 37
2005 29
2006 27
2007 27
2008 31
2009 44
2010 37
2011 39
2012 42
2013 36
2014 44
2015 33
2016 25
2017 30
2018 43
2019 49
2020 39
2021 52
2022 94
2023 122
2024 188
2025 60

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,100 results

Results by year

Filters applied: . Clear all
Page 1
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
Xiong Y, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, Fisher M, Jiang Y, Che F, Wang L, Zhou L, Dai H, Liu X, Pan Y, Duan C, Xu Y, Xu A, Zong L, Tan Z, Ye W, Wang H, Wang Z, Hao M, Cao Z, Wang L, Wu S, Li H, Li Z, Zhao X, Wang Y; TRACE-III Investigators. Xiong Y, et al. N Engl J Med. 2024 Jul 18;391(3):203-212. doi: 10.1056/NEJMoa2402980. Epub 2024 Jun 14. N Engl J Med. 2024. PMID: 38884324 Clinical Trial.
BACKGROUND: Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. ...RESULTS: A total of 516 patients were enrolled; 264 were randomly assigned to receive tenecteplase and 252 to …
BACKGROUND: Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after …
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, Sangha N, Kim M, Froehler MT, Schwartz NE, Clark WM, Kircher CE, Yang M, Massaro L, Lu XY, Rippon GA, Broderick JP, Butcher K, Lansberg MG, Liebeskind DS, Nouh A, Schwamm LH, Campbell BCV; TIMELESS Investigators. Albers GW, et al. N Engl J Med. 2024 Feb 22;390(8):701-711. doi: 10.1056/NEJMoa2310392. Epub 2024 Feb 8. N Engl J Med. 2024. PMID: 38329148 Clinical Trial.
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. ...RESULTS: The trial enrolled 458 patients, 77.3% of wh …
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Info …
Tenecteplase Thrombolysis for Acute Ischemic Stroke.
Warach SJ, Dula AN, Milling TJ Jr. Warach SJ, et al. Stroke. 2020 Nov;51(11):3440-3451. doi: 10.1161/STROKEAHA.120.029749. Epub 2020 Oct 13. Stroke. 2020. PMID: 33045929 Free PMC article. Review.
Investigated as a thrombolytic for ischemic stroke over the past 15 years, tenecteplase is currently being studied in several phase 3 trials. Based on a systematic literature search, we provide a qualitative synthesis of published stroke clinical trials of tenecteplase …
Investigated as a thrombolytic for ischemic stroke over the past 15 years, tenecteplase is currently being studied in several phase 3 …
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, Schwamm LH, Fisher M, Che F, Dai H, Li D, Li R, Wang J, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X; TRACE-2 Investigators. Wang Y, et al. Lancet. 2023 Feb 25;401(10377):645-654. doi: 10.1016/S0140-6736(22)02600-9. Epub 2023 Feb 9. Lancet. 2023. PMID: 36774935 Clinical Trial.
BACKGROUND: There is increasing interest in replacing alteplase with tenecteplase as the preferred thrombolytic treatment for patients with acute ischaemic stroke. ...FINDINGS: Between June 12, 2021, and May 29, 2022, 1430 participants were enrolled and randomly assigned t …
BACKGROUND: There is increasing interest in replacing alteplase with tenecteplase as the preferred thrombolytic treatment for patient …
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, Thirunavukkarasu S, Khosravani H, Appireddy R, Moreau F, Gubitz G, Tkach A, Catanese L, Dowlatshahi D, Medvedev G, Mandzia J, Pikula A, Shankar J, Williams H, Field TS, Manosalva A, Siddiqui M, Zafar A, Imoukhuede O, Hunter G, Demchuk AM, Mishra S, Gioia LC, Jalini S, Cayer C, Phillips S, Elamin E, Shoamanesh A, Subramaniam S, Kate M, Jacquin G, Camden MC, Benali F, Alhabli I, Bala F, Horn M, Stotts G, Hill MD, Gladstone DJ, Poppe A, Sehgal A, Zhang Q, Lethebe BC, Doram C, Ademola A, Shamy M, Kenney C, Sajobi TT, Swartz RH; AcT Trial Investigators. Menon BK, et al. Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29. Lancet. 2022. PMID: 35779553 Clinical Trial.
FINDINGS: Between Dec 10, 2019, and Jan 25, 2022, 1600 patients were enrolled and randomly assigned to tenecteplase (n=816) or alteplase (n=784), of whom 1577 were included in the ITT population (n=806 tenecteplase; n=771 alteplase). ...In safety analyses, 27 (3.4%) …
FINDINGS: Between Dec 10, 2019, and Jan 25, 2022, 1600 patients were enrolled and randomly assigned to tenecteplase (n=816) or altepl …
Evolving Thrombolytics: from Alteplase to Tenecteplase.
Miller SE, Warach SJ. Miller SE, et al. Neurotherapeutics. 2023 Apr;20(3):664-678. doi: 10.1007/s13311-023-01391-3. Epub 2023 Jun 5. Neurotherapeutics. 2023. PMID: 37273127 Free PMC article. Review.
Randomized trials investigating tenecteplase in the delayed treatment window and with thrombectomy are ongoing, and their results are eagerly awaited. This paper provides an overview of completed and ongoing randomized trials and nonrandomized studies analyzing tenectep …
Randomized trials investigating tenecteplase in the delayed treatment window and with thrombectomy are ongoing, and their results are …
European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.
Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis GM, Fromm A, Kõrv J, Roaldsen MB, Katsanos AH, Tsivgoulis G. Alamowitch S, et al. Eur Stroke J. 2023 Mar;8(1):8-54. doi: 10.1177/23969873221150022. Epub 2023 Feb 2. Eur Stroke J. 2023. PMID: 37021186 Free PMC article.
For patients with AIS of <4.5 h duration who are eligible for IVT, we recommend against using tenecteplase at a dose of 0.40 mg/kg (low evidence, strong recommendation). For patients with AIS of <4.5 h duration with prehospital management with a mobile stroke unit wh …
For patients with AIS of <4.5 h duration who are eligible for IVT, we recommend against using tenecteplase at a dose of 0.40 mg/kg …
Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications.
Murphy LR, Hill TP, Paul K, Talbott M, Golovko G, Shaltoni H, Jehle D. Murphy LR, et al. Ann Emerg Med. 2023 Dec;82(6):720-728. doi: 10.1016/j.annemergmed.2023.03.022. Epub 2023 May 12. Ann Emerg Med. 2023. PMID: 37178103
There is evidence that tenecteplase has at least similar efficacy and safety outcomes compared with alteplase for stroke. In this study, we compared tenecteplase versus alteplase for acute stroke in a large retrospective US database (TriNetX) regarding the following …
There is evidence that tenecteplase has at least similar efficacy and safety outcomes compared with alteplase for stroke. In this stu …
Tenecteplase in Acute Stroke: What About the Children?
Sun LR, Wilson JL, Waak M, Kiskaddon A, Goldenberg NA, Jordan LC, Barry M. Sun LR, et al. Stroke. 2023 Jul;54(7):1950-1953. doi: 10.1161/STROKEAHA.123.042951. Epub 2023 May 25. Stroke. 2023. PMID: 37226774 Review.
Tenecteplase is replacing alteplase as the fibrinolytic agent of choice for the acute management of ischemic stroke in many adult stroke centers due to practical and pharmacokinetic advantages in the setting of similar outcomes. Although thrombolytic use is increasing for …
Tenecteplase is replacing alteplase as the fibrinolytic agent of choice for the acute management of ischemic stroke in many adult str …
Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
Meng X, Li S, Dai H, Lu G, Wang W, Che F, Geng Y, Sun M, Li X, Li H, Wang Y. Meng X, et al. JAMA. 2024 Nov 5;332(17):1437-1445. doi: 10.1001/jama.2024.14721. JAMA. 2024. PMID: 39264623 Free PMC article. Clinical Trial.
IMPORTANCE: Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg/kg in Chinese patients with acute ischemic stroke …
IMPORTANCE: Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing sin …
1,100 results